Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Agios Pharmaceuticals Inc
AGIO
Healthcare
Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined...
disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:AGIO)
New Post
View:
Posts & Comments
Threaded Posts
(275)
•••
whytestocks
X
Post by
whytestocks
on Oct 31, 2024 11:15pm
Agios Reports Business Highlights and Third Quarter 2024 Fin
BREAKING NEWS: $AGIO Agios Reports Business Highlights and Third Quarter 2024 Financial Results@ Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data
...more
(275)
•••
whytestocks
X
Post by
whytestocks
on Sep 28, 2024 7:15am
Where are the Opportunities in (AGIO)
BREAKING NEWS: $AGIO Where are the Opportunities in (AGIO)2024-09-28 06:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to
...more
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 12:59pm
Agios Pharmaceuticals (AGIO): Transforming Rare Disease Trea
https://beyondspx.com/2024/07/31/agios-pharmaceuticals-agio-transforming-rare-disease-treatment-with-groundbreaking-pk-activation/
(275)
•••
whytestocks
X
Post by
whytestocks
on May 28, 2024 1:15pm
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday
Breaking News: $AGIO Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? | BenzingaTuesday,@Agios Pharmaceuticals@Inc@(NASDAQ:AGIO) agreed to@sell its rights@to its 15% royalty on potential
...more
(275)
•••
whytestocks
X
Post by
whytestocks
on May 28, 2024 11:00am
Agios Announces $905 Million Purchase Agreement for Voraside
News; $AGIO Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty@ Royalty Pharma to Acquire Rights to Agios@ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million
...more
(4)
•••
AviseAnalytics
X
Post by
AviseAnalytics
on Feb 08, 2022 9:02am
5 BIOTECH STOCKS WITH MAJOR UPCOMING CATALYSTS
$AGIO $CYTK $ADGI $PHAT $ICPT Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden